This growth opportunity analysis examines the global biologics contract development and manufacturing organization (bio-CDMO) landscape across key regions, namely North America (NA); Europe; and Asia-Pacific (APAC).
• How can emerging business models such as reserved capacity and contract research development and manufacturing organization (CRDMO) services transform the traditional fee-for-service manufacturing services space?
• What are the major types of drug substances, cell expressions, nucleic acid-based products, and insect- and plant-based expression systems?
• How is the shift toward biologics boosting product pipelines and adoption?
• How can Bio-CDMOs provide the agility and flexibility required for next-generation modalities?
• Why is the pharmaceutical landscape moving toward right shoring, which involves keeping parts of the supply chain and processes in strategic locations to deliver the desired combination of cost and efficiency?
Sign up for a complimentary Growth Pipeline Dialog™
A Growth Pipeline Dialog is a structured open discussion with our growth experts providing unparalleled industry intelligence, technology advancements, and proven implementation best practices. This discussion will spark innovative thinking and help generate a pipeline of growth opportunities you can leverage to maximize your company’s future growth potential.
